Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2018 05:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA)...
June 08, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

WATERTOWN, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
May 30, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018

WATERTOWN, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
May 09, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update

3-month Phase 2 data presented at PANLAR 2018 indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less...
May 02, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Date of First Quarter 2018 Financial Results Conference Call

WATERTOWN, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
May 01, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
April 10, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress

3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared with...
April 03, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018

WATERTOWN, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
March 20, 2018 16:01 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018

WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
March 15, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

SEL-212 Severe Gout Program on Track; Additional Phase 2 Data for Higher Dose Cohorts to be Presented on April 9th or 10th, 2018 at PANLAR CongressPhase 1 Clinical Trial of SEL-403 for Mesothelioma...